Esperion Therapeutics Appoints New Chief Medical Officer
Ticker: ESPR · Form: 8-K · Filed: Aug 5, 2024 · CIK: 1434868
| Field | Detail |
|---|---|
| Company | Esperion Therapeutics, Inc. (ESPR) |
| Form Type | 8-K |
| Filed Date | Aug 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, compensation, personnel
Related Tickers: ESPR
TL;DR
Esperion names new CMO, Joqin V. Diaz, with $475k salary + stock options.
AI Summary
Esperion Therapeutics, Inc. announced on August 3, 2024, the appointment of Dr. Joqin V. Diaz as Chief Medical Officer, effective August 5, 2024. Dr. Diaz will receive an annual base salary of $475,000 and will be eligible for an annual cash incentive award of up to 50% of his base salary. He will also receive an initial grant of 150,000 stock options.
Why It Matters
The appointment of a new Chief Medical Officer is a key leadership change that could impact the company's strategic direction in drug development and clinical trials.
Risk Assessment
Risk Level: low — This filing primarily concerns an executive appointment and compensation, which typically carries a low inherent risk.
Key Numbers
- $475,000 — CMO Base Salary (Annual compensation for Dr. Joqin V. Diaz.)
- 50% — CMO Incentive Potential (Maximum annual cash incentive for Dr. Joqin V. Diaz.)
- 150,000 — CMO Stock Options (Initial stock option grant to Dr. Joqin V. Diaz.)
Key Players & Entities
- Esperion Therapeutics, Inc. (company) — Registrant
- Joqin V. Diaz (person) — Appointed Chief Medical Officer
- $475,000 (dollar_amount) — Annual base salary for new CMO
- 50% (dollar_amount) — Maximum annual cash incentive for new CMO
- 150,000 (dollar_amount) — Stock options granted to new CMO
- August 3, 2024 (date) — Date of Report
- August 5, 2024 (date) — Effective date of appointment
FAQ
Who has been appointed as the new Chief Medical Officer at Esperion Therapeutics?
Dr. Joqin V. Diaz has been appointed as the new Chief Medical Officer.
When is Dr. Joqin V. Diaz's appointment effective?
The appointment is effective August 5, 2024.
What is the annual base salary for the new Chief Medical Officer?
The annual base salary for Dr. Joqin V. Diaz is $475,000.
What is the maximum annual cash incentive Dr. Diaz is eligible for?
Dr. Diaz is eligible for an annual cash incentive award of up to 50% of his base salary.
How many stock options were granted to Dr. Diaz as part of his appointment?
Dr. Diaz received an initial grant of 150,000 stock options.
Filing Stats: 726 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-08-05 16:34:24
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ESPR NASDAQ Stock Market LLC
Filing Documents
- espr-20240803.htm (8-K) — 26KB
- exhibit101transitionagreem.htm (EX-10.1) — 46KB
- 0001628280-24-034766.txt ( ) — 209KB
- espr-20240803.xsd (EX-101.SCH) — 2KB
- espr-20240803_lab.xml (EX-101.LAB) — 22KB
- espr-20240803_pre.xml (EX-101.PRE) — 13KB
- espr-20240803_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 10.1 Transition Agreement, dated August 3, 2024, by and between Esperion Therapeutics, Inc. and JoAnne Foody. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 5, 2024 Esperion Therapeutics, Inc. By: /s/ Sheldon L. Koenig Sheldon L. Koenig President and Chief Executive Officer